V1, Here's the protocol for ovarian cancer:
Summary: Study of patients with advanced epithelial ovarian cancer
Profile Page: Columbia-Presbyterian Medical Center, New York, NY
This is a study of patients with a history of advanced epithelial ovarian cancer, that after remission,
have an abnormally elevated concentration of CA125. Patients will be treated with TARGRETIN, a
synthetic retinoic analog, in this study.
Patients must be at least 18 years old and asymptomatic after complete remission, except for high
CA125 levels. Patients should not have other invasive malignancy and no chemotherapy, radiation
therapy, or any other therapy within 4 weeks before the initiation of study treatment.
Contact:
Diana Catz, Ph.D., Project Coordinator
Columbia-Presbyterian Medical Center
Columbia-Presbyterian Cancer Center
161 Fort Washington Ave.
10 Floor, Room 1082
New York, NY 10032
Telephone: 212-305-0177
Fax: 212-305-0178
Email: catz@wccta.ccc.columbia.edu |
